Prilenia
Naarden · Biotechnology, Health Care, Therapeutics
Prilenia is a clinical-stage biotech company focused on developing novel treatments for neurodegenerative and neurodevelopmental disorders. Our lead asset is Pridopidine, a first-in-class oral drug candidate with an established safety profile and potential in multiple movement disorders and neurodegenerative diseases affecting adults and children. Pridopidine is currently being evaluated for
Key facts
- Headquarters
- Naarden
- Employees
- 60
- Industries
- Biotechnology, Health Care, Therapeutics
- Status
- Private
- Website
- https://www.prilenia.com
- Company page
Recent activity at Prilenia
- : Prilenia Appoints Frederick (Rick) Munschauer as Chief Medical Officer
- : Prilenia Appoints Dr. Elisabeth Leiderman as Chief Financial Officer
- : Prilenia Therapeutics B.V. Appoints Rob Lauzen as Chief Financial Officer and Jason Marks, J.D. as Chief Legal Officer
- : Prilenia Therapeutics B.V. Appoints Dr. Jina Swartz, M.D. Ph.D. as Chief Medical Officer
- : Sv Health Investors Joins Prilenia Series B As The Company Prepares For Als And Hd Data Readouts In The Next 12 Months
- : Prilenia Closes Oversubscribed $43 Million In Series B Financing Round
Prilenia funding history
| Date | Round | Amount |
|---|---|---|
| Apr 2022 | Series B | Undisclosed |
| Nov 2021 | Series B | $43.0M |
Leadership
- Frederick (Rick) Munschauer, Chief Medical Officer
- Elisabeth Leiderman, Chief Financial Officer
- Jason Marks, Chief Legal Officer
- Rob Lauzen, Chief Financial Officer
- Michael R. Hayden, Chief Executive Officer
- Jina Swartz, Chief Medical Officer
Verified email and direct lines for Prilenia’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Prilenia in the news
- Prilenia and Ferrer Announce First Participant Enrolled in the “PREVAiLS” Phase 3 Study of Pridopidine in ALS - Business Wire (Mar 30, 2026)
- Prilenia and Ferrer Announce Authorization for EU Initiation of Confirmatory PRECISE-HD Study of Pridopidine in Huntington's Disease - Business Wire (Oct 22, 2026)
- Prilenia and Ferrer to Share New Pridopidine Data and PREVAiLS Study Updates at the NEALS Consortium 2026 Annual Meeting - Business Wire (Oct 28, 2026)
- Ferrer and Prilenia Announce Authorization for EU Initiation of Confirmatory PRECISE-HD Study of Pridopidine in Huntington's Disease - Business Wire (Oct 22, 2026)
- Clinical Trial Evidence of Association between Antidopaminergic Medications and Clinical Measurements of Huntington’s Disease Progression Published in Neurology - Business Wire (Oct 29, 2026)
- Prilenia Appoints Frederick (Rick) Munschauer, MD, FAAN, as Chief Medical Officer - Business Wire (Sep 08, 2026)
- Prilenia Appoints Dr. Elisabeth Leiderman as Chief Financial Officer - Business Wire (Apr 28, 2026)
Companies similar to Prilenia
- Oculis Holding AG · Biotechnology, Health Care, Therapeutics
- ISU Abxis · Biotechnology, Health Care, Therapeutics
- Altimmune · Biotechnology, Health Care, Therapeutics
- GentiBio · Biotechnology, Health Care, Therapeutics
- Enara Bio · Biotechnology, Health Care, Therapeutics
About Prilenia: questions and answers
What does Prilenia do?
Prilenia is a clinical-stage biotech company focused on developing novel treatments for neurodegenerative and neurodevelopmental disorders. Our lead asset is Pridopidine, a first-in-class oral drug candidate with an established safety profile and potential in multiple movement disorders and neurodegenerative diseases affecting adults and children. Pridopidine is currently being evaluated for
Where is Prilenia headquartered?
Prilenia is headquartered in Naarden.
How many employees does Prilenia have?
Prilenia has about 60 employees.
Has Prilenia raised funding?
Yes. Fundz has recorded 2 funding events for Prilenia. The most recent, Series B of Undisclosed, was in Apr 2022.
Who leads Prilenia?
Michael R. Hayden is a Chief Executive Officer at Prilenia.
What is the latest news on Prilenia?
On Sep 08, 2026, Prilenia Appoints Frederick (Rick) Munschauer as Chief Medical Officer
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy